

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

## Zelnorm (tegaserod)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Zelnorm (tegaserod)	May be subject to quantity limit

### APPROVAL CRITERIA

Requests for Zelnorm (tegaserod) may be approved if the following criteria is met:

- I. Individual is less than 65 years of age; **AND**
- II. Individual has a diagnosis of irritable bowel syndrome with constipation (IBS-C); **AND**
- III. The individual must have a previous trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of or insufficient response to two laxatives (e.g. polyethylene glycol (generic MiraLax), bisacodyl (Dulcolax), senna (Ex-lax)) (AGA 2013, 2019).

Requests for Zelnorm (tegaserod) may not be approved for the following:

- I. Individual has a history of myocardial infarction, stroke, transient ischemic attack, or angina; **OR**
- II. Individual has a history of ischemic colitis or other forms of intestinal ischemia; **OR**
- III. Individual has severe renal impairment (eGFR < 15 mL/min/1.73 m<sup>2</sup>) or end stage renal disease; **OR**
- IV. Individual has moderate or severe hepatic impairment (Child-Pugh B or C); **OR**
- V. Individual has a history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.  
CRX-ALL-0469-19

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

**Key References:**

1. American Gastroenterological Association, Bharucha AE, Dorn SD, Lembo A, Pressman A. American Gastroenterological Association medical position statement on constipation. *Gastroenterology*. 2013 Jan;144(1):211-7. Available from: [http://www.gastrojournal.org/article/S0016-5085\(12\)01545-4/pdf](http://www.gastrojournal.org/article/S0016-5085(12)01545-4/pdf). Accessed on: July 22, 2019.
2. American Gastroenterological Association, Crockett SD, Greer KB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. *Gastroenterology*. 2019 Jan;156(1): 218-226. Available from: [https://www.gastrojournal.org/article/S0016-5085\(18\)34782-6/pdf](https://www.gastrojournal.org/article/S0016-5085(18)34782-6/pdf). Accessed on: July 22, 2019.
3. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
4. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 9, 2019.
5. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
6. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.  
CRX-ALL-0469-19